Skip to content

Analgesic Efficacy and Psychological State Evaluation of Dezocine Combined with Sufentanil and Flurbiprofen in Postoperative Analgesia for Elderly Patients Undergoing Spinal Surgery

Analgesic Efficacy and Psychological State Evaluation of Dezocine Combined with Sufentanil and Flurbiprofen in Postoperative Analgesia for Elderly Patients Undergoing Spinal Surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108157
Enrollment
Unknown
Registered
2025-08-26
Start date
2025-09-15
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain after Spinal Surgery

Interventions

Group A: Dezocine + Sufentanil Group :PCIA uses 0.3mg/kg dezosine 2ug/kg sufentanil 0.2mg/kg ondansetron
Group B: Flurbiprofen Axetil + Sufentanil Group :PCIA uses flurbiprofen ester 200mg 2ug/kg sufentanil 0.2mg/kg ondansetron
Group C: Dezocine + Sufentanil + Flurbiprofen Axetil Group:PCIA uses 0.15 mg/kg dezoxin, flurbiprofen ester 150 mg, 1ug/kg sufentanil, and 0.2 mg/kg ondansetron

Sponsors

The Third Affiliated Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age>=65 years old, <=85 years old; 2. ASA grade I-III; 3. Thoracolumbar spinal fusion and internal fixation surgery (1 to 2 segments); 4. The operation takes more than 1 hour and is less than 3 hours; 5. All patients signed the informed consent form with the approval of the hospital ethics committee.

Exclusion criteria

Exclusion criteria: 1. Patients who have had any cerebrovascular accident within 3 months, such as stroke, transient ischemic attack, etc.; 2. Those who have contraindications or allergies to the test drug and other anesthetic drugs; 3. History of neurological diseases; History of chronic pain; drug addiction and alcoholism; History of long-term opioid use; 4. Patients with severe organic lesions (coronary heart disease, severe hypertension, severe blood system dysfunction, abnormal liver and kidney function) during preoperative examination; 5. Body mass index (BMI) less than 18kg/m^2 or >=28kg/m^2; 6. Patients who have participated in other clinical trials within one month before the start of this study; 7. Patients with other conditions that the investigator deems unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
VAS Resting and Activity Pain Scores;

Secondary

MeasureTime frame
Beck Depression Inventory (BDI);Zung Self-Rating Anxiety Scale (SAS) Score;Ramsay Score;

Countries

China

Contacts

Public ContactLiang Qingchun

The Third Affiliated Hospital of Southern Medical University

qingchun@i.smu.edu.cn+86 189 2230 1461

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026